Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inmune Bio Inc (NQ: INMB )

11.47 +0.63 (+5.86%)
Streaming Delayed Price Updated: 1:39 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 41,647
Open 10.83
Bid (Size) 11.40 (2)
Ask (Size) 11.53 (4)
Prev. Close 10.84
Today's Range 10.83 - 11.73
52wk Range 6.500 - 14.74
Shares Outstanding 17,703,692
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
From INmune Bio, Inc.
Via GlobeNewswire

Performance

YTD
+2.27%
+2.27%
1 Month
-3.41%
-3.41%
3 Month
-2.84%
-2.84%
6 Month
+64.40%
+64.40%
1 Year
+64.40%
+64.40%

More News

Read More
INmune Bio: Q4 Earnings Insights
Via Benzinga
A Preview Of INmune Bio's Earnings
Via Benzinga
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
From INmune Bio, Inc.
Via GlobeNewswire
INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Earnings Scheduled For March 28, 2024
Via Benzinga
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
From INmune Bio, Inc.
Via GlobeNewswire
Why Is Elevai Labs (ELAB) Stock Up Today?
Via InvestorPlace
Why Elevai Labs Stock Is Trading Higher
Via Benzinga
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
From Elevai Labs Inc.
Via GlobeNewswire
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Via Investor's Business Daily
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority
From INmune Bio, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.